Daiichi Sankyo and AstraZeneca’s (AZN) supplemental biologics license application for Enhertu followed by paclitaxel, trastuzumab and pertuzumab has been accepted for review in the U.S. for the neoadjuvant treatment of adult patients with HER2 positive stage 2 or stage 3 breast cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- White House announces deal with Pfizer for ‘most-favored-nation pricing’
- AstraZeneca’s Tezepelumab Study: Real-World Insights on Asthma and Cough
- Trump says other drugmakers to join Pfizer with ‘most favored nation’ prices
- Fintech Giant Revolut Could Make History With Cross-Atlantic $75B IPO
- GlaxoSmithKline Stock (GSK) Up as CEO Emma Walmsley Steps Down for Luke Miels